Shenzhen News Network December 23, 2019 (Reporter Tian Zhiqiang correspondent Niu Xiaoyu) On December 23, the Shenzhen Enterprise Public Opinion Research Institute released the twenty-first batch of corporate public opinion lists. This list focuses on two industries, real estate and medical care. The public opinion list of the medical and healthcare industry is composed of the hot public opinion event rankings (red and black) in the medical and healthcare industry and the public image ranking of companies in the medical and healthcare industry.
The list and description are published as follows:
I. Ranking of hot public opinion events in the healthcare industry
Red List: China's first original anticancer drug approved by the FDA
On November 15th, Zebutinib, a BTK inhibitor independently developed by BeiGene, was approved by the US Food and Drug Administration (FDA), becoming the first new anti-cancer drug completely developed by Chinese companies and approved by the FDA. .
It is understood that Zebutinib is a new powerful BTK inhibitor that can be used to treat patients with mantle cell lymphoma who have previously received at least one therapy. Zebutinib is currently being used as a single drug or in combination with other therapies to conduct clinical trials in the treatment of multiple lymphomas.
The data show that in clinical trials for mantle cell lymphoma, more than 84% of patients receiving Zebutinib achieved an overall response.
Blacklist: Correction of unqualified circulation of pharyngitis tablets in the pharmaceutical industry
Recently, the pharmaceutical quality announcement of Anhui Province showed that the amendment to the pharyngitis tablet with batch number 180606 produced by Changchun High-tech Pharmaceutical Co., Ltd. of the pharmaceutical industry group did not meet the standard requirements on the microbial limit project.
The data show that this is not the first time that the pharmaceutical industry has failed to correct the product. From 2012 to 2017, the pharmaceutical company's medicines were repeatedly unqualified, and its Antelope Cold Capsule product was suspected of illegally adding industrial gelatin, and the chromium content exceeded the standard. Due to the intentional fabrication of false inspection reports, it revised the pharmaceutical industry's withdrawn GMP certificate.
At present, for the reasons related to the drug disqualification and other related issues, Amend Pharmaceutical has not responded.
The list of hot events in the pharmaceutical and health products industry explains:
This list mainly uses computer systems to automatically collect, sort, and analyze public opinion data, combined with the screening and research of public opinion analysts, on the hot public opinion in the field of medical and healthcare products during the period from November 1 to November 30, 2019. The incident (mainly related to the public opinion of the enterprise) was obtained through a comprehensive assessment. The main evaluation indicators include news report index, Weibo diffusion index, forum participation index, and overseas speculation index. Based on the above indicators, the comprehensive impact index of events is obtained according to relevant algorithms, and they are sorted by index size.
Second, the public image ranking of companies in the healthcare industry
In terms of the public image rankings of the pharmaceutical and healthcare industry, the scores of the corporate public image rankings are basically stable and have not fluctuated greatly. In terms of ranking, Hengrui Medicine still tops the corporate public image list, and this is the 17th consecutive time that it has topped the list. In addition, the second place on the list was won by Shanghai Pharmaceuticals, and the third place was still won by Health Yuan.
Public image ranking of companies in the medical and health products industry:
This list is based on publicly available information and data, from financial indicators (total assets, operating income, net profit, revenue growth rate, profit growth rate, etc.), innovation indicators (enterprises in terms of technology product research and development, business model innovation The five dimensions of investment status and response to national macro policy guidance, industrial development trends), public opinion exposure, and negative impacts. For the period from November 1 to November 30, 2019, companies in the medical and health products industry The comprehensive evaluation and ranking of the public image of the company aims to carry out comprehensive evaluation of brand image building, promotion strategies, public relations maintenance, brand influence and other aspects of companies in the pharmaceutical and health care products industry, which not only helps relevant companies find the right brand positioning , Development direction, and also provide consumers and investors with scientific, fair, independent reference to consumption and investment decisions.
It is understood that the Shenzhen Enterprise Public Opinion Research Institute is led by the Shenzhen News Network, in conjunction with Shenzhen Network Media Association, Shenzhen Quality Consumer Research Institute, Shenzhen Quality Association, Shenzhen Enterprise Credit Management Association, and Shenzhen Keyun Technology Co., Ltd. Non-governmental non-profit organization initiated. The institute aims to carry out research and work on the occurrence, development, monitoring, and guidance of corporate public opinion, and to assist the government in the research, management, and guidance of corporate public opinion. Source: Shenzhen News Network